Pseudomonas aeruginosa alters Staphylococcus aureus sensitivity to vancomycin in a biofilm model of cystic fibrosis infection

mBio

Volumn 8, Issue 4, 2017, Pages

  Orazi, Giulia ^a   O’Toole, George A ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Antibiotic tolerance; Biofilms; Cystic fibrosis; Polymicrobial; Pseudomonas; Staphylococcus aureus

Indexed keywords

2 HEPTYL 4 HYDROXYQUINOLINE 1 OXIDE; PLASTIC; PYOCHELIN; PYOVERDINE; SIDEROPHORE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL FACTOR;

ANOXIA; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM MUTANT; BIOFILM; COCULTURE; CYSTIC FIBROSIS; CYTOTOXICITY ASSAY; EPITHELIUM CELL; IN VITRO STUDY; LUNG INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; SUPERNATANT; TRANSMISSION ELECTRON MICROSCOPY; BIOLOGICAL MODEL; CELL CULTURE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; HYPOXIA; METABOLISM; MICROBIOLOGY; ORGANISMAL INTERACTION; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; BIOFILMS; BIOLOGICAL FACTORS; CELLS, CULTURED; CYSTIC FIBROSIS; HUMANS; HYPOXIA; MICROBIAL INTERACTIONS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 85029071416     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00873-17     Document Type: Article

References (64)

1. Heijerman H. 2005. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros 4(Suppl 2):3–5. https://doi.org/10.1016/j.jcf.2005.05.005.
2. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, Wolfgang MC. 2012. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 7:e45001. https://doi.org/10.1371/journal.pone.0045001.
3. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman L, Daniels TWV, Patel N, Forbes B, Bruce KD. 2012. Longterm cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 67:867-873. https://doi.org/10.1136/thoraxjnl-2011-200932.
4. Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, Sogin ML, O’Toole GA. 2013. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome 1:27. https://doi.org/10.1186/2049-2618-1-27.
5. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, Young VB, LiPuma JJ. 2012. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A 109:5809-5814. https://doi.org/10.1073/pnas.1120577109.
6. Lim YW, Schmieder R, Haynes M, Willner D, Furlan M, Youle M, Abbott K, Edwards R, Evangelista J, Conrad D, Rohwer F. 2013. Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. J Cyst Fibros 12:154-164. https://doi.org/10.1016/j.jcf.2012.07.009.
7. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA. 2013. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One 8:e62917. https://doi.org/10.1371/journal.pone.0062917.
8. Filkins LM, O’Toole GA. 2015. Cystic fibrosis lung infections: polymicrobial, complex, and hard to treat. PLoS Pathog 11:e1005258. https://doi.org/10.1371/journal.ppat.1005258.
9. Cystic Fibrosis Foundation. 2015. Cystic Fibrosis Foundation patient registry 2015 annual data report. Cystic Fibrosis Foundation, Bethesda, MD.
10. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U, Andersen GL, Brown R, Fujimura KE, Wu B, Tran D, Koff J, Kleinhenz ME, Nielson D, Brodie EL, Lynch SV. 2010. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 5:e11044. https://doi.org/10.1371/journal.pone.0011044.
11. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:91–100. https://doi.org/10.1002/ppul.10127.
12. Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, Marsh P, Prehar K, Pope CE, Blackledge M, Deziel E, Bruce KD, Ramsey BW, Gibson RL, Burns JL, Hoffman LR. 2013. Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis 57:384-391. https://doi.org/10.1093/cid/cit270.
13. Com G, Carroll JL, Castro MM, Tang X, Jambhekar S, Berlinski A. 2014. Predictors and outcome of low initial forced expiratory volume in 1 second measurement in children with cystic fibrosis. J Pediatr 164: 832–838. https://doi.org/10.1016/j.jpeds.2013.11.064.
14. Limoli DH, Yang J, Khansaheb MK, Helfman B, Peng L, Stecenko AA, Goldberg JB. 2016. Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes. Eur J Clin Microbiol Infect Dis 35:947–953. https://doi.org/10.1007/s10096-016-2621-0.
15. Mitchell G, Seguin DL, Asselin AE, Deziel E, Cantin AM, Frost EH, Michaud S, Malouin F. 2010. Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide. BMC Microbiol 10:33. https://doi.org/10.1186/1471-2180-10-33.
16. Fugère A, Lalonde Séguin D, Mitchell G, Déziel E, Dekimpe V, Cantin AM, Frost E, Malouin F. 2014. Interspecific small molecule interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic fibrosis patients. PLoS One 9:e86705. https://doi.org/10.1371/journal.pone.0086705.
17. Hoffman LR, Déziel E, D’Argenio DA, Lépine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI. 2006. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 103:19890–19895. https://doi.org/10.1073/pnas.0606756104.
18. Lightbown JW. 1954. An antagonist of streptomycin and dihydrostreptomycin produced by Pseudomonas aeruginosa. J Gen Microbiol 11: 477–492. https://doi.org/10.1099/00221287-11-3-477.
19. Mashburn LM, Jett AM, Akins DR, Whiteley M. 2005. Staphylococcus aureus serves as an iron source for Pseudomonas aeruginosa during in vivo coculture. J Bacteriol 187:554-566. https://doi.org/10.1128/JB.187.2.554-566.2005.
20. Rüger M, Ackermann M, Reichl U. 2014. Species-specific viability analysis of Pseudomonas aeruginosa, Burkholderia cepacia and Staphylococcus aureus in mixed culture by flow cytometry. BMC Microbiol 14:56. https://doi.org/10.1186/1471-2180-14-56.
21. Nguyen AT, Jones JW, Ruge MA, Kane MA, Oglesby-Sherrouse AG. 2015. Iron depletion enhances production of antimicrobials by Pseudomonas aeruginosa. J Bacteriol 197:2265–2275. https://doi.org/10.1128/JB.00072-15.
22. Filkins LM, Graber JA, Olson DG, Dolben EL, Lynd LR, Bhuju S, O’Toole GA. 2015. Coculture of Staphylococcus aureus with Pseudomonas aeruginosa drives S. aureus towards fermentative metabolism and reduced viability in a cystic fibrosis model. J Bacteriol 197:2252–2264. https://doi.org/10.1128/JB.00059-15.
23. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35:322–332. https://doi.org/10.1016/j.ijantimicag.2009.12.011.
24. Lam J, Chan R, Lam K, Costerton JW. 1980. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 28:546-556.
25. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762–764. https://doi.org/10.1038/35037627.
26. Høiby N, Ciofu O, Bjarnsholt T. 2010. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 5:1663–1674. https://doi.org/10.2217/fmb.10.125.
27. Hogardt M, Heesemann J. 2013. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr Top Microbiol Immunol 358:91–118. https://doi.org/10.1007/82_2011_199.
28. Kozarich JW, Strominger JL. 1978. A membrane enzyme from Staphylococcus aureus which catalyzes transpeptidase, carboxypeptidase, and penicillinase activities. J Biol Chem 253:1272–1278.
29. Finan JE, Archer GL, Pucci MJ, Climo MW. 2001. Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45:3070-3075. https://doi.org/10.1128/AAC.45.11.3070-3075.2001.
30. Memmi G, Filipe SR, Pinho MG, Fu Z, Cheung A. 2008. Staphylococcus aureus PBP4 is essential for beta-lactam resistance in communityacquired methicillin-resistant strains. Antimicrob Agents Chemother 52: 3955–3966. https://doi.org/10.1128/AAC.00049-08.
31. Anderson GG, Moreau-Marquis S, Stanton BA, O’Toole GA. 2008. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 76:1423–1433. https://doi.org/10.1128/IAI.01373-07.
32. Hohnadel D, Haas D, Meyer J-M. 1986. Mapping of mutations affecting pyoverdine production in Pseudomonas aeruginosa. FEMS Microbiol Lett 36:195–199. https://doi.org/10.1111/j.1574-6968.1986.tb01695.x.
33. Voggu L, Schlag S, Biswas R, Rosenstein R, Rausch C, Götz F. 2006. Microevolution of cytochrome bd oxidase in staphylococci and its implication in resistance to respiratory toxins released by Pseudomonas. J Bacteriol 188:8079–8086. https://doi.org/10.1128/JB.00858-06.
34. Biswas L, Biswas R, Schlag M, Bertram R, Gotz F. 2009. Small-colony variant selection as a survival strategy for Staphylococcus aureus in the presence of Pseudomonas aeruginosa. Appl Environ Microbiol 75: 6910–6912. https://doi.org/10.1128/AEM.01211-09.
35. Lépine F, Déziel E, Milot S, Rahme LG. 2003. A stable isotope dilution assay for the quantification of the Pseudomonas quinolone signal in Pseudomonas aeruginosa cultures. Biochim Biophys Acta 1622:36–41. https://doi.org/10.1016/S0304-4165(03)00103-X.
36. Déziel E, Lépine F, Milot S, He J, Mindrinos MN, Tompkins RG, Rahme LG. 2004. Analysis of Pseudomonas aeruginosa 4-hydroxy-2-alkylquinolines (HAQs) reveals a role for 4-hydroxy-2-heptylquinoline in cell-to-cell communication. Proc Natl Acad Sci U S A 101:1339-1344. https://doi.org/10.1073/pnas.0307694100.
37. Hess DJ, Henry-Stanley MJ, Lusczek ER, Beilman GJ, Wells CL. 2013. Anoxia inhibits biofilm development and modulates antibiotic activity. J Surg Res 184:488–494. https://doi.org/10.1016/j.jss.2013.04.049.
38. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. 1996. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 38:589-597. https://doi.org/10.1093/jac/38.4.589.
39. Suller MTE, Lloyd D. 2002. The antibacterial activity of vancomycin towards Staphylococcus aureus under aerobic and anaerobic conditions. J Appl Microbiol 92:866–872. https://doi.org/10.1046/j.1365-2672.2002.01594.x.
40. Lightbown JW, Jackson FL. 1956. Inhibition of cytochrome systems of heart muscle and certain bacteria by the antagonists of dihydrostreptomycin: 2-alkyl-4-hydroxyquinoline N-oxides. Biochem J 63:130-137. https://doi.org/10.1042/bj0630130.
41. Machan ZA, Taylor GW, Pitt TL, Cole PJ, Wilson R. 1992. 2-Heptyl-4-hydroxyquinoline N-oxide, an antistaphylococcal agent produced by Pseudomonas aeruginosa. J Antimicrob Chemother 30:615-623. https://doi.org/10.1093/jac/30.5.615.
42. Miller MH, Edberg SC, Mandel LJ, Behar CF, Steigbigel NH. 1980. Gentamicin uptake in wild-type and aminoglycoside-resistant small-colony mutants of Staphylococcus aureus. Antimicrob Agents Chemother 18: 722–729. https://doi.org/10.1128/AAC.18.5.722.
43. Balwit JM, van Langevelde P, Vann JM, Proctor RA. 1994. Gentamicinresistant menadione and hemin auxotrophic Staphylococcus aureus persist within cultured endothelial cells. J Infect Dis 170:1033–1037. https://doi.org/10.1093/infdis/170.4.1033.
44. von Eiff C, Heilmann C, Proctor RA, Woltz C, Peters G, Gotz F. 1997. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J Bacteriol 179:4706–4712. https://doi.org/10.1128/jb.179.15.4706-4712.1997.
45. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4:295–305. https://doi.org/10.1038/nrmicro1384.
46. Wise RI, Spink WW. 1954. The influence of antibiotics on the origin of small colonies (G variants) of Micrococcus pyogenes var. aureus. J Clin Invest 33:1611–1622. https://doi.org/10.1172/JCI103041.
47. Quie PG. 1969. Microcolonies (G-variants) of Staphylococcus aureus. Yale J Biol Med 41:394–403.
48. Proctor RA, Balwit JM, Vesga O. 1994. Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections. Infect Agents Dis 3:302–312.
49. Proctor RA, van Langevelde P, Kristjansson M, Maslow JN, Arbeit RD. 1995. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis 20:95–102. https://doi.org/10.1093/clinids/20.1.95.
50. Cui L, Ma X, Sato K, Okuma K, Tenover FC, Mamizuka EM, Gemmell CG, Kim MN, Ploy MC, El-Solh N, Ferraz V, Hiramatsu K. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41:5–14. https://doi.org/10.1128/JCM.41.1.5-14.2003.
51. Cázares-Dominguez V, Cruz-Córdova A, Ochoa SA, Escalona G, Arellano-Galindo J, Rodríguez-Leviz A, Hernandez-Castro R, López-Villegas EO, Xicohtencatl-Cortes J. 2015. Vancomycin tolerant, methicillin-resistant Staphylococcus aureus reveals the effects of vancomycin on cell wall thickening. PLoS One 10:e0118791. https://doi.org/10.1371/journal.pone.0118791.
52. Conti SF, Jacobs NJ, Gray CT. 1968. Ultrastructure and respiratory capacity of Staphylococcus and Bacillus grown under aerobic and anaerobic conditions. J Bacteriol 96:554-556.
53. Ferreira MT, Manso AS, Gaspar P, Pinho MG, Neves AR. 2013. Effect of oxygen on glucose metabolism: utilization of lactate in Staphylococcus aureus as revealed by in vivo NMR studies. PLoS One 8:e58277. https://doi.org/10.1371/journal.pone.0058277.
54. Kopf SH, Sessions AL, Cowley ES, Reyes C, Van Sambeek L, Hu Y, Orphan VJ, Kato R, Newman DK. 2016. Trace incorporation of heavy water reveals slow and heterogeneous pathogen growth rates in cystic fibrosis sputum. Proc Natl Acad Sci U S A 113:E110-E116. https://doi.org/10.1073/pnas.1512057112.
55. Mates SM, Patel L, Kaback HR, Miller MH. 1983. Membrane potential in anaerobically growing Staphylococcus aureus and its relationship to gentamicin uptake. Antimicrob Agents Chemother 23:526-530. https://doi.org/10.1128/AAC.23.4.526.
56. Morales DK, Grahl N, Okegbe C, Dietrich LEP, Jacobs NJ, Hogan DA. 2013. Control of Candida albicans metabolism and biofilm formation by Pseudomonas aeruginosa phenazines. mBio 4:e00526-12. https://doi.org/10.1128/mBio.00526-12.
57. Lindsay AK, Morales DK, Liu Z, Grahl N, Zhang A, Willger SD, Myers LC, Hogan DA. 2014. Analysis of Candida albicans mutants defective in the Cdk8 module of mediator reveal links between metabolism and biofilm formation. PLoS Genet 10:e1004567. https://doi.org/10.1371/journal.pgen.1004567.
58. Grahl N, Demers EG, Lindsay AK, Harty CE, Willger SD, Piispanen AE, Hogan DA. 2015. Mitochondrial activity and Cyr1 are key regulators of Ras1 activation of C. albicans virulence pathways. PLoS Pathog 11: e1005133. https://doi.org/10.1371/journal.ppat.1005133.
59. Abdel-Mawgoud AM, Lepine F, Deziel E. 2010. Rhamnolipids: diversity of structures, microbial origins and roles. Appl Microbiol Biotechnol 86: 1323–1336. https://doi.org/10.1007/s00253-010-2498-2.
60. Limoli DH, Whitfield GB, Kitao T, Ivey ML, Davis MR, Grahl N, Hogan DA, Rahme LG, Howell PL, O’Toole GA, Goldberg JB. 2017. Pseudomonas aeruginosa alginate overproduction promotes coexistence with Staphylococcus aureus in a model of cystic fibrosis respiratory infection. mBio 8:e00186-17. https://doi.org/10.1128/mBio.00186-17.
61. Connell JL, Ritschdorff ET, Whiteley M, Shear JB. 2013. 3D printing of microscopic bacterial communities. Proc Natl Acad Sci U S A 110: 18380–18385. https://doi.org/10.1073/pnas.1309729110.
62. DeLeon S, Clinton A, Fowler H, Everett J, Horswill AR, Rumbaugh KP. 2014. Synergistic interactions of Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro wound model. Infect Immun 82:4718–4728. https://doi.org/10.1128/IAI.02198-14.
63. Price KE, Naimie AA, Griffin EF, Bay C, O’Toole GA. 2015. Tobramycintreated Pseudomonas aeruginosa PA14 enhances Streptococcus constellatus 7155 biofilm formation in a cystic fibrosis model system. J Bacteriol 198:237–247. https://doi.org/10.1128/JB.00705-15.
64. Essar DW, Eberly L, Hadero A, Crawford IP. 1990. Identification and characterization of genes for a second anthranilate synthase in Pseudomonas aeruginosa: interchangeability of the two anthranilate synthases and evolutionary implications. J Bacteriol 172:884-900. https://doi.org/10.1128/jb.172.2.884-900.1990.